| Cash Flow | 2026-03-31 |
|---|---|
| Net loss | -22,687 |
| Equity-based compensation | 1,318 |
| Depreciation and amortization | 73 |
| Non-cash lease expense | -153 |
| Accretion of discount on available-for-sale debt securities | 816 |
| Prepaid expenses and other current assets | -1,166 |
| Other non-current assets | 1,016 |
| Accounts payable | -52 |
| Accrued expenses and other current liabilities | 434 |
| Operating lease liabilities | -157 |
| Net cash used in operating activities | -21,584 |
| Purchases of available-for-sale debt securities | 15,735 |
| Purchases of property and equipment | 112 |
| Net cash used in investing activities | -15,847 |
| Payment of offering costs | 414 |
| Principal payments on finance lease | 46 |
| Net cash used in financing activities | -460 |
| Effect of foreign exchange rate changes on cash and cash equivalents | -223 |
| Net decrease in cash and cash equivalents | -38,114 |
| Cash and cash equivalents at beginning of period | 87,974 |
| Cash and cash equivalents at end of period | 49,860 |
Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings, Inc. (COAG)